| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Neoplasms | 137 | 2024 | 631 | 17.040 |
Why?
|
| Chordoma | 24 | 2023 | 163 | 4.910 |
Why?
|
| Sacrum | 21 | 2023 | 132 | 3.570 |
Why?
|
| Spinal Cord Compression | 19 | 2019 | 151 | 3.290 |
Why?
|
| Radiosurgery | 37 | 2024 | 1330 | 3.100 |
Why?
|
| Spinal Fractures | 13 | 2024 | 132 | 2.430 |
Why?
|
| Spine | 23 | 2022 | 293 | 2.150 |
Why?
|
| Thoracic Vertebrae | 17 | 2020 | 186 | 1.780 |
Why?
|
| Orthopedic Procedures | 12 | 2018 | 146 | 1.680 |
Why?
|
| Osteotomy | 8 | 2020 | 100 | 1.260 |
Why?
|
| Fractures, Compression | 6 | 2024 | 42 | 1.230 |
Why?
|
| Joint Instability | 8 | 2020 | 88 | 1.040 |
Why?
|
| Laser Therapy | 7 | 2018 | 411 | 1.040 |
Why?
|
| Lumbar Vertebrae | 12 | 2021 | 245 | 0.960 |
Why?
|
| Neurosurgical Procedures | 10 | 2023 | 609 | 0.960 |
Why?
|
| Neoplasm Recurrence, Local | 36 | 2024 | 10035 | 0.900 |
Why?
|
| Neck Injuries | 1 | 2023 | 32 | 0.890 |
Why?
|
| Spinal Cord Neoplasms | 6 | 2022 | 142 | 0.860 |
Why?
|
| Spinal Fusion | 8 | 2023 | 149 | 0.860 |
Why?
|
| Cervical Vertebrae | 9 | 2017 | 205 | 0.850 |
Why?
|
| Treatment Outcome | 68 | 2023 | 32848 | 0.750 |
Why?
|
| Fractures, Bone | 1 | 2023 | 291 | 0.740 |
Why?
|
| Spinal Diseases | 4 | 2021 | 125 | 0.690 |
Why?
|
| Ganglia, Spinal | 6 | 2021 | 237 | 0.670 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 3 | 2017 | 96 | 0.670 |
Why?
|
| Chondrosarcoma | 5 | 2023 | 216 | 0.660 |
Why?
|
| Giant Cell Tumor of Bone | 3 | 2017 | 52 | 0.650 |
Why?
|
| Middle Aged | 96 | 2024 | 86204 | 0.640 |
Why?
|
| Hyperthermia, Induced | 4 | 2017 | 510 | 0.610 |
Why?
|
| Male | 108 | 2023 | 123000 | 0.600 |
Why?
|
| Retrospective Studies | 58 | 2024 | 37905 | 0.600 |
Why?
|
| Adult | 89 | 2021 | 77950 | 0.600 |
Why?
|
| Humans | 171 | 2024 | 261506 | 0.600 |
Why?
|
| Aged | 80 | 2023 | 70117 | 0.590 |
Why?
|
| Telomerase | 1 | 2019 | 525 | 0.550 |
Why?
|
| Osteosarcoma | 5 | 2017 | 929 | 0.550 |
Why?
|
| Female | 109 | 2023 | 141928 | 0.540 |
Why?
|
| Fibula | 4 | 2020 | 146 | 0.530 |
Why?
|
| Surgery, Computer-Assisted | 3 | 2021 | 255 | 0.520 |
Why?
|
| Sarcoma | 6 | 2024 | 1725 | 0.520 |
Why?
|
| Magnetic Resonance Imaging | 21 | 2023 | 7702 | 0.520 |
Why?
|
| Quality of Life | 10 | 2021 | 4532 | 0.490 |
Why?
|
| Preoperative Care | 2 | 2019 | 1529 | 0.470 |
Why?
|
| Postoperative Complications | 23 | 2020 | 5542 | 0.460 |
Why?
|
| Follow-Up Studies | 30 | 2020 | 14889 | 0.450 |
Why?
|
| Pedicle Screws | 2 | 2023 | 10 | 0.440 |
Why?
|
| Carmustine | 3 | 2006 | 214 | 0.430 |
Why?
|
| Aged, 80 and over | 40 | 2019 | 29902 | 0.410 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2016 | 2326 | 0.410 |
Why?
|
| Decompression, Surgical | 8 | 2018 | 143 | 0.400 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2021 | 852 | 0.370 |
Why?
|
| Pain Measurement | 11 | 2018 | 953 | 0.370 |
Why?
|
| Disease Models, Animal | 4 | 2017 | 7222 | 0.370 |
Why?
|
| Sarcoma, Ewing | 3 | 2018 | 406 | 0.360 |
Why?
|
| Ependymoma | 3 | 2014 | 242 | 0.350 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2011 | 192 | 0.350 |
Why?
|
| Young Adult | 28 | 2020 | 21445 | 0.340 |
Why?
|
| Prospective Studies | 20 | 2020 | 12873 | 0.340 |
Why?
|
| Stereotaxic Techniques | 6 | 2016 | 172 | 0.330 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 263 | 0.330 |
Why?
|
| Radiography | 10 | 2020 | 1904 | 0.330 |
Why?
|
| Zygapophyseal Joint | 2 | 2021 | 15 | 0.330 |
Why?
|
| Multiple Myeloma | 5 | 2007 | 2138 | 0.320 |
Why?
|
| Kidney Neoplasms | 7 | 2017 | 3022 | 0.320 |
Why?
|
| Free Tissue Flaps | 4 | 2020 | 372 | 0.320 |
Why?
|
| Gliosarcoma | 3 | 2003 | 29 | 0.320 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 2576 | 0.320 |
Why?
|
| Survival Rate | 16 | 2018 | 12221 | 0.320 |
Why?
|
| Prognosis | 17 | 2019 | 21713 | 0.300 |
Why?
|
| Paclitaxel | 4 | 2021 | 1996 | 0.290 |
Why?
|
| Psoas Muscles | 1 | 2006 | 12 | 0.290 |
Why?
|
| Osteoma, Osteoid | 2 | 2016 | 22 | 0.290 |
Why?
|
| Chondrosarcoma, Mesenchymal | 1 | 2006 | 17 | 0.280 |
Why?
|
| Giant Cell Tumors | 2 | 2017 | 33 | 0.280 |
Why?
|
| Orthopedic Fixation Devices | 2 | 2003 | 20 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 7551 | 0.280 |
Why?
|
| Polymers | 3 | 2023 | 223 | 0.280 |
Why?
|
| Mice, Nude | 2 | 2014 | 4307 | 0.270 |
Why?
|
| Bone Cysts, Aneurysmal | 2 | 2016 | 21 | 0.270 |
Why?
|
| Pain Management | 4 | 2020 | 668 | 0.270 |
Why?
|
| Skull Base Neoplasms | 2 | 2021 | 314 | 0.260 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2021 | 393 | 0.260 |
Why?
|
| Neuralgia | 2 | 2019 | 251 | 0.250 |
Why?
|
| Sensory Receptor Cells | 2 | 2017 | 141 | 0.250 |
Why?
|
| Neoplasms, Fibrous Tissue | 1 | 2004 | 7 | 0.250 |
Why?
|
| Palliative Care | 6 | 2018 | 2037 | 0.240 |
Why?
|
| Mesoderm | 1 | 2006 | 404 | 0.240 |
Why?
|
| Benzophenones | 1 | 2023 | 12 | 0.240 |
Why?
|
| Nervous System Diseases | 2 | 2020 | 500 | 0.240 |
Why?
|
| Neoplasm Metastasis | 6 | 2022 | 5112 | 0.230 |
Why?
|
| Giant Cells | 1 | 2004 | 69 | 0.230 |
Why?
|
| Combined Modality Therapy | 12 | 2017 | 8865 | 0.230 |
Why?
|
| Survival Analysis | 12 | 2019 | 9180 | 0.230 |
Why?
|
| Cancer Pain | 2 | 2018 | 312 | 0.230 |
Why?
|
| Europe | 3 | 2019 | 649 | 0.220 |
Why?
|
| Spondylolisthesis | 1 | 2002 | 8 | 0.220 |
Why?
|
| Fractures, Stress | 1 | 2002 | 11 | 0.220 |
Why?
|
| Parietal Lobe | 1 | 2003 | 66 | 0.220 |
Why?
|
| Plastics | 1 | 2023 | 93 | 0.220 |
Why?
|
| Wound Healing | 3 | 2019 | 815 | 0.220 |
Why?
|
| Radiotherapy Dosage | 9 | 2018 | 3842 | 0.220 |
Why?
|
| Clinical Decision-Making | 2 | 2016 | 524 | 0.220 |
Why?
|
| Lung Neoplasms | 7 | 2017 | 11538 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2020 | 6207 | 0.220 |
Why?
|
| Microsurgery | 1 | 2005 | 244 | 0.220 |
Why?
|
| Hemipelvectomy | 2 | 2020 | 40 | 0.210 |
Why?
|
| Cross-Sectional Studies | 8 | 2019 | 4314 | 0.210 |
Why?
|
| Adolescent | 23 | 2020 | 31252 | 0.210 |
Why?
|
| Radiotherapy, Conformal | 4 | 2017 | 902 | 0.210 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2005 | 261 | 0.200 |
Why?
|
| Reproducibility of Results | 9 | 2018 | 6009 | 0.200 |
Why?
|
| Epidural Neoplasms | 2 | 2018 | 7 | 0.190 |
Why?
|
| Hyperalgesia | 3 | 2017 | 238 | 0.190 |
Why?
|
| Nociceptors | 1 | 2020 | 86 | 0.190 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 80 | 0.190 |
Why?
|
| Thoracoplasty | 1 | 2020 | 20 | 0.190 |
Why?
|
| Oncologists | 1 | 2022 | 134 | 0.180 |
Why?
|
| Guanine | 1 | 2000 | 151 | 0.180 |
Why?
|
| Kyphosis | 4 | 2017 | 43 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2020 | 129 | 0.180 |
Why?
|
| Pelvic Bones | 1 | 2020 | 95 | 0.180 |
Why?
|
| Evidence-Based Medicine | 3 | 2016 | 1085 | 0.180 |
Why?
|
| Conservative Treatment | 1 | 2020 | 58 | 0.180 |
Why?
|
| Brain Neoplasms | 5 | 2006 | 4849 | 0.180 |
Why?
|
| Denosumab | 2 | 2017 | 68 | 0.180 |
Why?
|
| Rats | 11 | 2021 | 6086 | 0.180 |
Why?
|
| Digestive System Neoplasms | 1 | 2020 | 82 | 0.180 |
Why?
|
| Transcriptome | 2 | 2019 | 1859 | 0.180 |
Why?
|
| Wound Closure Techniques | 1 | 2019 | 28 | 0.180 |
Why?
|
| Carcinoma | 2 | 2017 | 2578 | 0.170 |
Why?
|
| Interleukin-2 | 1 | 2003 | 842 | 0.170 |
Why?
|
| Titanium | 2 | 2023 | 61 | 0.170 |
Why?
|
| Margins of Excision | 1 | 2021 | 285 | 0.170 |
Why?
|
| Decision Trees | 1 | 2019 | 178 | 0.170 |
Why?
|
| Polymethyl Methacrylate | 2 | 2017 | 41 | 0.170 |
Why?
|
| Treatment Refusal | 1 | 2020 | 128 | 0.170 |
Why?
|
| Electrophysiological Phenomena | 1 | 2019 | 75 | 0.170 |
Why?
|
| Neurosurgeons | 1 | 2018 | 17 | 0.170 |
Why?
|
| Reoperation | 6 | 2020 | 1382 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 222 | 0.160 |
Why?
|
| Internationality | 2 | 2017 | 208 | 0.160 |
Why?
|
| Risk Factors | 8 | 2023 | 17523 | 0.160 |
Why?
|
| NAV1.7 Voltage-Gated Sodium Channel | 1 | 2017 | 5 | 0.160 |
Why?
|
| Bone Transplantation | 3 | 2020 | 134 | 0.160 |
Why?
|
| Thoracic Wall | 1 | 2020 | 183 | 0.160 |
Why?
|
| Thermography | 1 | 2018 | 59 | 0.160 |
Why?
|
| Fibroma | 1 | 2018 | 85 | 0.160 |
Why?
|
| Spinal Nerve Roots | 2 | 2010 | 65 | 0.150 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2018 | 2104 | 0.150 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2017 | 203 | 0.150 |
Why?
|
| Osteoblastoma | 1 | 2017 | 15 | 0.150 |
Why?
|
| Asphyxia | 1 | 2017 | 21 | 0.150 |
Why?
|
| Fetal Proteins | 1 | 2017 | 28 | 0.150 |
Why?
|
| Recovery of Function | 3 | 2018 | 703 | 0.150 |
Why?
|
| Steroids | 2 | 2017 | 356 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2017 | 27 | 0.150 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2000 | 588 | 0.150 |
Why?
|
| Mollusca | 2 | 1993 | 11 | 0.150 |
Why?
|
| Surgical Flaps | 3 | 2020 | 927 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5319 | 0.150 |
Why?
|
| Neuronavigation | 1 | 2017 | 47 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2017 | 2218 | 0.150 |
Why?
|
| Rats, Inbred F344 | 5 | 2003 | 224 | 0.140 |
Why?
|
| Artifacts | 2 | 2023 | 532 | 0.140 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2016 | 79 | 0.140 |
Why?
|
| Skull Base | 1 | 2017 | 199 | 0.140 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2016 | 72 | 0.140 |
Why?
|
| T-Box Domain Proteins | 1 | 2017 | 156 | 0.140 |
Why?
|
| Surveys and Questionnaires | 7 | 2021 | 5687 | 0.140 |
Why?
|
| Embolization, Therapeutic | 3 | 2016 | 551 | 0.140 |
Why?
|
| Treatment Failure | 4 | 2017 | 1391 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 945 | 0.130 |
Why?
|
| Osteochondroma | 1 | 2015 | 12 | 0.130 |
Why?
|
| Smell | 2 | 1993 | 125 | 0.130 |
Why?
|
| Biomarkers, Tumor | 5 | 2017 | 10331 | 0.130 |
Why?
|
| TRPV Cation Channels | 1 | 2015 | 76 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 1350 | 0.130 |
Why?
|
| Interneurons | 2 | 1993 | 144 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 925 | 0.130 |
Why?
|
| Psychometrics | 2 | 2018 | 937 | 0.130 |
Why?
|
| Neurilemmoma | 1 | 2016 | 127 | 0.130 |
Why?
|
| Ilium | 2 | 2013 | 54 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 5 | 2021 | 2231 | 0.130 |
Why?
|
| Thyroid Neoplasms | 2 | 2016 | 1866 | 0.130 |
Why?
|
| Diskectomy | 2 | 2005 | 10 | 0.130 |
Why?
|
| Photomicrography | 1 | 2014 | 26 | 0.130 |
Why?
|
| Radiation Injuries | 2 | 2016 | 1411 | 0.120 |
Why?
|
| Spinal Cord Injuries | 2 | 2016 | 374 | 0.120 |
Why?
|
| Bone Screws | 2 | 2005 | 84 | 0.120 |
Why?
|
| Length of Stay | 2 | 2018 | 1900 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2016 | 1987 | 0.120 |
Why?
|
| Neoplasm Transplantation | 3 | 2009 | 1519 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 1 | 2014 | 66 | 0.120 |
Why?
|
| Radiation Tolerance | 1 | 2017 | 629 | 0.120 |
Why?
|
| Back Pain | 2 | 2005 | 61 | 0.120 |
Why?
|
| Pain, Postoperative | 3 | 2015 | 610 | 0.120 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 148 | 0.120 |
Why?
|
| Glioma | 2 | 2006 | 1963 | 0.120 |
Why?
|
| Hemangioma | 1 | 2015 | 154 | 0.120 |
Why?
|
| North America | 3 | 2018 | 314 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2021 | 2063 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2021 | 2292 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 1879 | 0.110 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2017 | 2370 | 0.110 |
Why?
|
| Femur | 1 | 2013 | 158 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Neurotransmitter Agents | 1 | 1993 | 159 | 0.110 |
Why?
|
| Disease-Free Survival | 6 | 2016 | 10001 | 0.110 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 4298 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2020 | 500 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 3101 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2018 | 1171 | 0.100 |
Why?
|
| Postoperative Care | 3 | 2019 | 739 | 0.100 |
Why?
|
| Heterografts | 1 | 2014 | 733 | 0.100 |
Why?
|
| Vertebroplasty | 1 | 2011 | 24 | 0.100 |
Why?
|
| Animals | 15 | 2021 | 59536 | 0.100 |
Why?
|
| Drug Implants | 2 | 2001 | 46 | 0.100 |
Why?
|
| Rectus Abdominis | 1 | 2012 | 100 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 4 | 2003 | 5395 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2009 | 5767 | 0.100 |
Why?
|
| Rare Diseases | 1 | 2014 | 351 | 0.100 |
Why?
|
| Analgesics, Opioid | 2 | 2018 | 1371 | 0.100 |
Why?
|
| Spinal Cord | 3 | 2017 | 690 | 0.100 |
Why?
|
| International Agencies | 1 | 2010 | 107 | 0.090 |
Why?
|
| Radiologists | 2 | 2022 | 163 | 0.090 |
Why?
|
| Observer Variation | 4 | 2014 | 671 | 0.090 |
Why?
|
| Polyradiculopathy | 1 | 2010 | 13 | 0.090 |
Why?
|
| Craniospinal Irradiation | 1 | 2012 | 128 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 7789 | 0.090 |
Why?
|
| Internal Fixators | 1 | 2010 | 14 | 0.090 |
Why?
|
| Pain | 4 | 2024 | 1658 | 0.090 |
Why?
|
| Diphosphonates | 2 | 2016 | 262 | 0.090 |
Why?
|
| Delphi Technique | 1 | 2010 | 210 | 0.090 |
Why?
|
| Spinal Canal | 1 | 2009 | 14 | 0.090 |
Why?
|
| Karnofsky Performance Status | 3 | 2016 | 175 | 0.090 |
Why?
|
| Disease Progression | 5 | 2020 | 6682 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2010 | 203 | 0.090 |
Why?
|
| Melanoma | 2 | 2017 | 5317 | 0.090 |
Why?
|
| Surgeons | 1 | 2016 | 519 | 0.090 |
Why?
|
| Fluoroscopy | 2 | 2017 | 232 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 13658 | 0.090 |
Why?
|
| Nitric Oxide | 2 | 2004 | 644 | 0.080 |
Why?
|
| Patient Selection | 5 | 2020 | 2055 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2006 | 15862 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2014 | 14551 | 0.080 |
Why?
|
| Child | 10 | 2020 | 29154 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 4971 | 0.080 |
Why?
|
| Incidence | 5 | 2019 | 5673 | 0.080 |
Why?
|
| Cohort Studies | 5 | 2020 | 9244 | 0.080 |
Why?
|
| Time Factors | 6 | 2020 | 12926 | 0.080 |
Why?
|
| Radiometry | 1 | 2013 | 980 | 0.080 |
Why?
|
| Epidural Space | 1 | 2007 | 42 | 0.080 |
Why?
|
| Radiotherapy | 3 | 2018 | 1824 | 0.070 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 860 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 4988 | 0.070 |
Why?
|
| Biopsy | 4 | 2010 | 3443 | 0.070 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2017 | 163 | 0.070 |
Why?
|
| Retroperitoneal Space | 1 | 2006 | 145 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 4320 | 0.070 |
Why?
|
| Chest Pain | 1 | 2007 | 155 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2015 | 2307 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2330 | 0.070 |
Why?
|
| Absorbable Implants | 1 | 2006 | 65 | 0.070 |
Why?
|
| Medical Records | 1 | 2007 | 415 | 0.070 |
Why?
|
| Biological Availability | 2 | 2003 | 214 | 0.070 |
Why?
|
| Patch-Clamp Techniques | 2 | 2017 | 388 | 0.070 |
Why?
|
| Bone Wires | 1 | 2005 | 9 | 0.070 |
Why?
|
| Fractures, Spontaneous | 3 | 2017 | 84 | 0.070 |
Why?
|
| Odontoid Process | 1 | 2005 | 13 | 0.070 |
Why?
|
| Occipital Bone | 1 | 2005 | 23 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 3981 | 0.060 |
Why?
|
| Brachiocephalic Veins | 1 | 2004 | 21 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.060 |
Why?
|
| Bone Plates | 1 | 2004 | 47 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2019 | 665 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2019 | 604 | 0.060 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 43 | 0.060 |
Why?
|
| Proton Therapy | 1 | 2015 | 1577 | 0.060 |
Why?
|
| Suture Techniques | 1 | 2006 | 319 | 0.060 |
Why?
|
| Vena Cava, Superior | 1 | 2004 | 78 | 0.060 |
Why?
|
| Pharynx | 1 | 2005 | 153 | 0.060 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 915 | 0.060 |
Why?
|
| Longitudinal Ligaments | 1 | 2003 | 6 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 216 | 0.060 |
Why?
|
| Pleural Diseases | 1 | 2004 | 57 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 3251 | 0.060 |
Why?
|
| Fistula | 1 | 2004 | 76 | 0.060 |
Why?
|
| Ketones | 1 | 2023 | 54 | 0.060 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2004 | 151 | 0.060 |
Why?
|
| Biodegradation, Environmental | 1 | 2003 | 19 | 0.060 |
Why?
|
| Chondroitin Sulfates | 1 | 2003 | 21 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 129 | 0.060 |
Why?
|
| Gelatin | 1 | 2003 | 49 | 0.060 |
Why?
|
| Lumbosacral Region | 1 | 2003 | 49 | 0.060 |
Why?
|
| Microscopy, Electron | 1 | 2004 | 600 | 0.060 |
Why?
|
| Atlanto-Axial Joint | 1 | 2003 | 25 | 0.060 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2003 | 49 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2003 | 164 | 0.060 |
Why?
|
| Thalidomide | 1 | 2006 | 569 | 0.060 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2003 | 27 | 0.060 |
Why?
|
| Encephalocele | 1 | 2003 | 53 | 0.050 |
Why?
|
| Osteoporosis | 1 | 2005 | 241 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 1270 | 0.050 |
Why?
|
| Microspheres | 1 | 2003 | 210 | 0.050 |
Why?
|
| Action Potentials | 2 | 2017 | 560 | 0.050 |
Why?
|
| Nervous System Neoplasms | 1 | 2002 | 36 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 462 | 0.050 |
Why?
|
| Standard of Care | 1 | 2024 | 243 | 0.050 |
Why?
|
| Sacrococcygeal Region | 1 | 2002 | 37 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 589 | 0.050 |
Why?
|
| Ganglioneuroma | 1 | 2002 | 41 | 0.050 |
Why?
|
| Patient Positioning | 2 | 2017 | 195 | 0.050 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1144 | 0.050 |
Why?
|
| Triazenes | 1 | 2001 | 2 | 0.050 |
Why?
|
| Cerebellar Diseases | 1 | 2003 | 89 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2004 | 675 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 3578 | 0.050 |
Why?
|
| Vasospasm, Intracranial | 1 | 2001 | 22 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1165 | 0.050 |
Why?
|
| Prostheses and Implants | 1 | 2003 | 295 | 0.050 |
Why?
|
| Emergencies | 1 | 2003 | 202 | 0.050 |
Why?
|
| Brain Stem Neoplasms | 1 | 2002 | 108 | 0.050 |
Why?
|
| Anastomosis, Surgical | 2 | 2013 | 371 | 0.050 |
Why?
|
| Fiducial Markers | 1 | 2021 | 96 | 0.050 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2000 | 69 | 0.050 |
Why?
|
| Astrocytes | 1 | 2004 | 368 | 0.050 |
Why?
|
| Craniotomy | 1 | 2003 | 304 | 0.050 |
Why?
|
| Bone Cements | 3 | 2006 | 45 | 0.050 |
Why?
|
| Ultrasonics | 1 | 2020 | 69 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2004 | 499 | 0.050 |
Why?
|
| Imidazoles | 1 | 2006 | 999 | 0.050 |
Why?
|
| Aorta | 1 | 2004 | 692 | 0.050 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2021 | 226 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4892 | 0.050 |
Why?
|
| Recurrence | 3 | 2017 | 4758 | 0.050 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2021 | 75 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2023 | 615 | 0.040 |
Why?
|
| Logistic Models | 2 | 2019 | 3441 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2004 | 400 | 0.040 |
Why?
|
| Soft Tissue Injuries | 1 | 2019 | 51 | 0.040 |
Why?
|
| Mutation | 1 | 2019 | 15179 | 0.040 |
Why?
|
| Paracrine Communication | 1 | 2000 | 128 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 4744 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 123 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2000 | 253 | 0.040 |
Why?
|
| Spider Venoms | 1 | 2017 | 10 | 0.040 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 434 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 590 | 0.040 |
Why?
|
| Sodium Channel Blockers | 1 | 2017 | 37 | 0.040 |
Why?
|
| Calcium | 2 | 2015 | 1537 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2019 | 5637 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2004 | 1656 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2003 | 1271 | 0.040 |
Why?
|
| Curettage | 1 | 2017 | 22 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2000 | 1313 | 0.040 |
Why?
|
| International Cooperation | 1 | 2018 | 323 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 208 | 0.040 |
Why?
|
| Electromyography | 1 | 2017 | 226 | 0.040 |
Why?
|
| Azabicyclo Compounds | 1 | 2017 | 36 | 0.040 |
Why?
|
| Ganglia | 2 | 1993 | 20 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 135 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2017 | 130 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2018 | 665 | 0.040 |
Why?
|
| Glutamates | 2 | 1993 | 130 | 0.030 |
Why?
|
| Decision Support Techniques | 1 | 2021 | 622 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2017 | 259 | 0.030 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 15694 | 0.030 |
Why?
|
| Cancer Care Facilities | 2 | 2015 | 884 | 0.030 |
Why?
|
| Mice | 4 | 2015 | 34495 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 280 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 178 | 0.030 |
Why?
|
| Doxycycline | 1 | 2016 | 178 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2017 | 298 | 0.030 |
Why?
|
| Medulloblastoma | 1 | 2000 | 540 | 0.030 |
Why?
|
| Radiology, Interventional | 1 | 2016 | 138 | 0.030 |
Why?
|
| United States | 4 | 2016 | 15433 | 0.030 |
Why?
|
| Motor Disorders | 1 | 2014 | 6 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 239 | 0.030 |
Why?
|
| Serotonin | 2 | 1993 | 264 | 0.030 |
Why?
|
| Walking | 2 | 2009 | 277 | 0.030 |
Why?
|
| Time | 1 | 2015 | 178 | 0.030 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2017 | 304 | 0.030 |
Why?
|
| Dopamine | 2 | 1993 | 312 | 0.030 |
Why?
|
| Glutamic Acid | 2 | 1993 | 309 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2015 | 245 | 0.030 |
Why?
|
| Confidence Intervals | 2 | 2007 | 756 | 0.030 |
Why?
|
| Laminectomy | 2 | 2005 | 52 | 0.030 |
Why?
|
| Fura-2 | 1 | 1993 | 13 | 0.030 |
Why?
|
| Biogenic Monoamines | 1 | 1993 | 7 | 0.030 |
Why?
|
| Delayed-Action Preparations | 2 | 2006 | 208 | 0.030 |
Why?
|
| Iliac Vein | 1 | 2013 | 38 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 6942 | 0.030 |
Why?
|
| Femoral Vein | 1 | 2013 | 66 | 0.030 |
Why?
|
| Iliac Artery | 1 | 2013 | 108 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1993 | 333 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 1742 | 0.030 |
Why?
|
| Gene Expression | 1 | 2020 | 3570 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2000 | 1616 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2000 | 3821 | 0.030 |
Why?
|
| Algorithms | 2 | 2017 | 3890 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 4975 | 0.030 |
Why?
|
| Paresis | 1 | 2011 | 54 | 0.030 |
Why?
|
| Efficiency | 1 | 2012 | 99 | 0.030 |
Why?
|
| Benzamides | 1 | 2017 | 1832 | 0.020 |
Why?
|
| Water | 1 | 2013 | 361 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2017 | 2450 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Cadaver | 1 | 2011 | 237 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 785 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 629 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1945 | 0.020 |
Why?
|
| Calibration | 1 | 2011 | 337 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 671 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2011 | 338 | 0.020 |
Why?
|
| Nerve Net | 1 | 1993 | 257 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1014 | 0.020 |
Why?
|
| Comorbidity | 1 | 2016 | 2352 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2010 | 139 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 1450 | 0.020 |
Why?
|
| Global Health | 1 | 2014 | 657 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 1380 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 356 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2012 | 514 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 2594 | 0.020 |
Why?
|
| Brazil | 1 | 2009 | 165 | 0.020 |
Why?
|
| Radiation Oncology | 1 | 2014 | 529 | 0.020 |
Why?
|
| Narcotics | 1 | 2009 | 123 | 0.020 |
Why?
|
| Italy | 1 | 2009 | 236 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 476 | 0.020 |
Why?
|
| Neoplasms | 3 | 2016 | 15193 | 0.020 |
Why?
|
| Graft Survival | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 2009 | 149 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 592 | 0.020 |
Why?
|
| Canada | 1 | 2009 | 429 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2017 | 1823 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2291 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1053 | 0.020 |
Why?
|
| Robotics | 1 | 2011 | 359 | 0.020 |
Why?
|
| Brain | 3 | 2000 | 4113 | 0.020 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2017 | 1833 | 0.020 |
Why?
|
| Salvage Therapy | 1 | 2015 | 2054 | 0.020 |
Why?
|
| Injections, Intraventricular | 1 | 2006 | 114 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 978 | 0.020 |
Why?
|
| Research Design | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 435 | 0.020 |
Why?
|
| Diskectomy, Percutaneous | 1 | 2005 | 2 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2017 | 4053 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 5377 | 0.020 |
Why?
|
| Contraindications | 1 | 2005 | 150 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2004 | 51 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2006 | 198 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2004 | 36 | 0.020 |
Why?
|
| Low Back Pain | 1 | 2004 | 83 | 0.010 |
Why?
|
| Immobilization | 1 | 2003 | 93 | 0.010 |
Why?
|
| Iatrogenic Disease | 1 | 2004 | 183 | 0.010 |
Why?
|
| Rats, Nude | 1 | 2002 | 32 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 750 | 0.010 |
Why?
|
| Taxoids | 1 | 2006 | 967 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2005 | 575 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2003 | 245 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 1162 | 0.010 |
Why?
|
| Body Height | 1 | 2003 | 231 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8223 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2002 | 159 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 598 | 0.010 |
Why?
|
| Respiration | 1 | 2003 | 447 | 0.010 |
Why?
|
| Particle Accelerators | 1 | 2003 | 352 | 0.010 |
Why?
|
| Pelvis | 1 | 2003 | 362 | 0.010 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2001 | 95 | 0.010 |
Why?
|
| Intestines | 1 | 2005 | 686 | 0.010 |
Why?
|
| Vasodilation | 1 | 2001 | 205 | 0.010 |
Why?
|
| Movement | 1 | 2003 | 556 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 1204 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 2489 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 6311 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 2803 | 0.010 |
Why?
|
| Antineoplastic Agents | 2 | 2016 | 14289 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2003 | 561 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 13310 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 2000 | 374 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 2314 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 11965 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 4938 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 6869 | 0.010 |
Why?
|
| Microelectrodes | 1 | 1993 | 52 | 0.010 |
Why?
|
| Olfactory Pathways | 1 | 1993 | 47 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1993 | 185 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 1993 | 122 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 1993 | 190 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 1993 | 424 | 0.010 |
Why?
|
| Neuronal Plasticity | 1 | 1993 | 304 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 1618 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 6150 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2000 | 3341 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2000 | 8873 | 0.000 |
Why?
|